Clinical Trial Update: A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients [Phase 2]

View source ↗

Summary

Phase 2 safety extension study assessing long-term safety of QGE031 (ligelizumab) in chronic spontaneous urticaria; completed with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spontaneous Urticaria

Drugs mentioned

• QGE031

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Spontaneous Urticaria | Phase 2 | Status: COMPLETED | Results posted: 2020-08-14